



Molecular Research of Neuroinflammation and Neurogenesis

Guest Editor:

Dr. Hui-Yun Chang

Institute of Systems
Neuroscience, National Tsing
Hua University, Hsinchu City
30013, Taiwan

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editor

The nature of neurogenesis and its integration into a functional circuit is more complex than for other cells. We are relatively certain that widespread differences in neurogenesis, such as larger brain sizes in males than females, larger eye sizes in females than males, and a higher neurogenesis in young individuals, have become accepted in this field. As illustrated in the beautiful drawings of Santiago Ramon y Cajal of the brain, we are equally sure that it is only possible in some individuals for the consequences of neurogenesis to lead to illness or mortality. Together, we must test the concept of differences in neurogenesis as a disease neuropathology and illustrate the idea of neurogenesis as evolutionary constrained, genetical organized developmental processes emerge from a wide range of studies, including neurogenetics and neurobiology. In this Special Issue, we welcome papers that focus on molecular biology and treatments of diseases, which aid in understanding the importance of both basic neurogenesis and clinical-related disease treatment studies: Neuroinflammation and neurogenesis; Neurogenesis and brain glial cells and microglia; Neurogenesis and neurodegeneration.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI